Catalog No.
YHC05702
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Ala40-Gln536
Predicted molecular weight
58.04 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P04062
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Lysosomal acid glucosylceramidase, Lysosomal acid GCase, 3.2.1.45, Acid beta-glucosidase, Alglucerase, Beta-glucocerebrosidase, Beta-GC, Beta-glucosylceramidase 1, Cholesterol glucosyltransferase, SGTase, 2.4.1.-, Cholesteryl-beta-glucosidase, 3.2.1.-, D-glucosyl-N-acylsphingosine glucohydrolase, Glucosylceramidase beta 1, Imiglucerase, Lysosomal cholesterol glycosyltransferase, Lysosomal galactosylceramidase, 3.2.1.46, Lysosomal glycosylceramidase, GBA1, GBA, GC, GLUC
Olfactory Perception in Parkinson's Disease: The Impact of GBA1 Variants (Sidransky Syndrome)., PMID:40508068
Hepatic Inactivation of Carnitine Palmitoyltransferase 1a Lowers ApoB-Containing Lipoproteins in Mice., PMID:40501382
Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom., PMID:40492480
Peroxisome Proliferator-Activated Receptors (PPARs) May Mediate the Neuroactive Effects of Probiotic Metabolites: An In Silico Approach., PMID:40429654
Microbiota dysbiosis impact on the immune system dysregulation in Huntington's disease (HD)., PMID:40414643
Application of IVDr NMR spectroscopy to stratify Parkinson's disease with absolute quantitation of blood serum metabolites and lipoproteins., PMID:40404791
A novel allosteric GCase modulator prevents Tau accumulation in GBA1WT and GBA1L444P/L444P cellular models., PMID:40399377
Protective Effect of the LRRK2 Kinase Inhibition in Human Fibroblasts Bearing the Genetic Variant GBA1 K198E: Implications for Parkinson's Disease., PMID:40397198
Sphingolipid metabolism-related genes as diagnostic markers in pneumonia-induced sepsis: the AUG model., PMID:40394027
Flavonoids from Shiliangcha (Chimonanthus salicifolius) Alleviate Brain Aging in d-Galactose-Induced Senescent Mice through Gut Microbiota., PMID:40388484
Targeting the Gut-Brain Axis with Plant-Derived Essential Oils: Phytocannabinoids and Beyond., PMID:40362887
Allosteric Modulation of GCase Enhances Lysosomal Activity and Reduces ER Stress in GCase-Related Disorders., PMID:40362629
LncRNA PVT1 promotes proliferation and migration in gallbladder adenocarcinoma by modulating miR-2355-5p/AGO1 axis., PMID:40346419
250 cases of "type 2 Gaucher disease": A novel system of clinical categorisation and evidence of genotype: Phenotype correlation., PMID:40339406
Combined assessment of blood glucocerebrosidase activity and α-synuclein levels in GBA1 mutation carriers: A novel potential biomarker., PMID:40339261
AAV delivery of GBA1 suppresses α-synuclein accumulation in Parkinson's disease models and restores functions in Gaucher's disease models., PMID:40333681
Identification of Novel Mutations in Patients Affected by Gaucher Disease., PMID:40332757
Peripheral Immune pattern in a genetic cohort of p.A53T alpha-synuclein carriers., PMID:40328209
Impact of LRRK2 and GBA variants on orthostatic hypotension in patients with Parkinson's disease., PMID:40314780
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)., PMID:40292288
Population-Specific Differences in Pathogenic Variants of Genes Associated with Monogenic Parkinson's Disease., PMID:40282414
Sidransky Syndrome-GBA1-Related Parkinson's Disease and Its Targeted Therapies., PMID:40244386
Do Nitrosative Stress Molecules Hold Promise as Biomarkers for Multiple Sclerosis?, PMID:40244291
Ketogenic Diet and Gut Microbiota: Exploring New Perspectives on Cognition and Mood., PMID:40238374
High Agreement Across Laboratories Between Different Alpha-Synuclein Seed Amplification Protocols., PMID:40237217
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis., PMID:40214505
Clinical and Laboratory Characteristics of Gaucher Disease Caused by Complex Heterozygous Mutation., PMID:40209771
Commander complex regulates lysosomal function and is implicated in Parkinson's disease risk., PMID:40209002
Modeling bone marrow microenvironment and hematopoietic dysregulation in Gaucher disease through VavCre mediated Gba deletion., PMID:40197748
Exome sequencing of a Portuguese cohort of early-onset Alzheimer's disease implicates the X-linked lysosomal gene GLA., PMID:40185916
Disease-Modifying Therapies in Parkinson's Disease., PMID:40185524
The number and frequency of mucosal-associated invariant T (MAIT), γδ T, and innate lymphoid cells (ILCs) altered in patients with type I Gaucher disease., PMID:40184787
Genetic variants associated with idiopathic Parkinson's disease in Latin America: A systematic review., PMID:40178685
LONG-NEXT: A new accurate and efficient NGS-based method for GBA1 analysis in Parkinson disease., PMID:40157138
Rare loss-of-function variants in HECTD2 and AKAP11 confer risk of bipolar disorder., PMID:40133559
Challenges in Gaucher disease: Perspectives from an expert panel., PMID:40112481
Treating critical bone defects by using core-shell biological scaffold to regulate Fibrosis-Osteogenic homeostasis., PMID:40083837
Phenylacetylcarbinol biotransformation by disrupted yeast cells using ultrasonic treatment in conjunction with a dipropylene glycol mediated biphasic emulsion system., PMID:40082633
Screening of intestinal protein signatures in pacific white-leg shrimp (Litopenaeus vannamei) with white feces syndrome by proteome., PMID:40064213
Effect of LRRK2 Inhibition on the Activity of Glucocerebrosidase in Patient-Specific Cells from Patients with Gaucher Disease., PMID:40058976
Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivo., PMID:40054502
Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in DLB and PD., PMID:40051075
Capturing what matters: Patient-reported LGI1-ANTibody encephalitis outcome RatiNg scale (LANTERN)., PMID:39996410
Identification of Cell Receptors Responsible for Recognition and Binding of Lipid Nanoparticles., PMID:39993835
Distinctive seizure signature in the first video case-control study of a naturally-occurring feline autoimmune encephalitis model., PMID:39984138
The effect of polygenic risk score on PD risk and phenotype in LRRK2 G2019S and GBA1 carriers., PMID:39973498
Atrophy-related corticospinal changes in advanced Parkinson's disease are associated with the genetic etiology of the disease., PMID:39957202
STAT1 inhibition promotes oxidative stress to sustain leukemia stem cell maintenance., PMID:39954714
Early-onset Parkinson's disease in a patient with a rare homozygous pathogenic GBA1 variant and no Gaucher disease symptoms., PMID:39954136
[Parkinson's disease: from genetics to targeted therapies]., PMID:39945455
For research use only. Not for human or drug use.
